相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)
W. Gerritsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer
Punam H. Patel et al.
ANNALS OF PHARMACOTHERAPY (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
Albana Cumashi et al.
CANCER LETTERS (2008)
Combination of docetaxel and recombinant vaccine enhances T-Cell responses and antitumor activity: Effects of docetaxel on immune enhancement
Charlie T. Garnett et al.
CLINICAL CANCER RESEARCH (2008)
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
Robert J. Lechleider et al.
CLINICAL CANCER RESEARCH (2008)
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
Ravi A. Madan et al.
CLINICAL CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy
Guru Sonpavde et al.
CLINICAL GENITOURINARY CANCER (2008)
Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design
R. A. Madan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical safety of a viral vector based prostate cancer vaccine strategy
Philip M. Arlen et al.
JOURNAL OF UROLOGY (2007)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Cancer vaccines: Moving beyond current paradigms
Jeffrey Schlom et al.
CLINICAL CANCER RESEARCH (2007)
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
Jeanny B. Aragon-Ching et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
PSA-based vaccines for the treatment of prostate cancer
Ravi A. Madan et al.
EXPERT REVIEW OF VACCINES (2006)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
PM Arlen et al.
CLINICAL CANCER RESEARCH (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation
GL Goldberg et al.
TRANSPLANTATION (2005)
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer
S Veeramani et al.
ENDOCRINE-RELATED CANCER (2005)
Vaccines with enhanced costimulation maintain high avidity memory CTL
SX Yang et al.
JOURNAL OF IMMUNOLOGY (2005)
Activation of thymic regeneration in mice and humans following androgen blockade
JS Sutherland et al.
JOURNAL OF IMMUNOLOGY (2005)
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells
SX Yang et al.
CLINICAL CANCER RESEARCH (2005)
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
PM Arlen et al.
JOURNAL OF UROLOGY (2005)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors
C Kudo-Saito et al.
CLINICAL CANCER RESEARCH (2005)
Multiple costimulatory modalities enhance CTL avidity
JW Hodge et al.
JOURNAL OF IMMUNOLOGY (2005)
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
JL Gulley et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Distribution of CD4(+)CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer
H Kawaida et al.
JOURNAL OF SURGICAL RESEARCH (2005)
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
CG Drake et al.
CANCER CELL (2005)
Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy
A Matejuk et al.
JOURNAL OF IMMUNOLOGY (2005)
Poxvirus vaccines for cancer and HIV therapy
S Essajee et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells
C Palena et al.
BLOOD (2004)
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing
M Chakraborty et al.
CANCER RESEARCH (2004)
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
CT Garnett et al.
CANCER RESEARCH (2004)
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology group
HL Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation
NG Chakraborty et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
M Chakraborty et al.
JOURNAL OF IMMUNOLOGY (2003)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Selective induction of high avidity CTL by altering the balance of signals from APC
S Oh et al.
JOURNAL OF IMMUNOLOGY (2003)
Immunoregulatory T cells in cancer immunotherapy
MA Morse et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
J Gulley et al.
PROSTATE (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation
EY Woo et al.
JOURNAL OF IMMUNOLOGY (2002)
Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes
H Tanaka et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Immune modulation by ionizing radiation and its implications for cancer immunotherapy
EJ Friedman
CURRENT PHARMACEUTICAL DESIGN (2002)
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
M Mercader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cutting edge:: Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells
CA Piccirillo et al.
JOURNAL OF IMMUNOLOGY (2001)
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules
JW Hodge et al.
VACCINE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
The immunological effects of taxanes
OTM Chan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Regulatory T cells: Key controllers of immunologic self-tolerance
S Sakaguchi
CELL (2000)
Cisplatin induces Fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells
I Matsuzaki et al.
ONCOLOGY (2000)
分享论文
